Warren A. Zuckerman, MD

  • Assistant Professor of Pediatrics at CUMC
  • Associate Fellowship Director
Warren A. Zuckerman, MD

Dr. Zuckerman joined the Columbia faculty as assistant clinical professor of pediatrics in July of 2011 after spending seven years as a pediatrics resident and pediatric cardiology fellow at Columbia University Medical Center. In 2009, Dr. Zuckerman was chosen as one of the chief fellows in the division of pediatric cardiology. His research interests include pediatric cardiomyopathies, donor- and recipient-related issues surrounding pediatric heart transplantation, and drug therapies for prevention and treatment of graft rejection following heart transplantation. He is part of the faculty with the Program for Pediatric Cardiomyopathy, Heart Failure, and Transplantation, and was named associate director of the fellowship in the division of pediatric cardiology in July of 2015.

The pediatric heart failure/transplant program at Columbia University Medical Center is not only clinically busy, but involved in several multicenter trials and registries, as well as institutional studies in order to help advance the field. The center has been involved in the Pediatric Cardiomyopathy Registry since 1990 and was one of the founding centers of the Pediatric Heart Transplant Study Group (PHTS), and has been an active member of the group since 1993. We are also involved in several trials as part of the Clinical Trials in Organ Transplantation in Children (CTOT-C) consortium evaluating such issues as anti-HLA sensitization, outcomes in heart transplant across a positive donor-specific crossmatch, quality of life and compliance post-transplant, as well as a multicenter study evaluating the detection of circulating donor-specific DNA as a predictor of rejection. Dr. Zuckerman is heavily involved in the CTOT-C clinical trials and also currently serves as the site principal investigator for the evaluation of the efficacy and safety of a novel anti-congestive therapy (Entresto) for pediatric heart failure patients.

Education & Training

  • New York University School of Medicine
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: Morgan Stanley Children's Hospital of NewYork-Presbyterian

Contact Info

  • Office Phone: 212-305-6575

Teaching Responsibilities

  • Associate Fellowship Director, Division of Pediatric Cardiology, 2015-Present
  • Member, Fellowship Clinical Competency Committee, Division of Pediatric Cardiology, 2013-Present
  • Member, Fellowship Education Subcommittee, Division of Pediatric Cardiology, 2013-Present
  • Member, Intern Selection Committee, Department of Pediatrics, 2012-Present

Committees / Societies / Memberships

  • Steering Committee Member, International Pediatric Heart Failure Registry, International Society for Heart and Lung Transplantation
  • Co-Editor, Cardiology Section, Current Pediatric Reports, 2014-2016
  • Supporting Member, International Society for Heart and Lung Transplantation
  • Supporting Member, American College of Cardiology
  • Supporting Member, Alpha Omega Alpha Medical Honor Society

Honors & Awards

  • Robyn Barst Fellow in Pulmonary Hypertension, 2010-2011
  • Welton M. Gersony Research Award, Division of Pediatric Cardiology, 2010
  • Chief Fellow, Division of Pediatric Cardiology, Columbia Presbyterian Medical Center, 2009-2010
  • Senior Resident Teaching Award, Department of Pediatrics, Columbia Presbyterian Medical Center, June 2007

Research Interests

  • Pre-transplant anti-HLA sensitization
  • Antibody-mediated rejection following pediatric heart transplantation
  • Donor- and recipient-related risk factors for outcomes after pediatric heart transplantation
  • Novel drugs to treat pediatric heart failure

NIH Grants

  • A MULTICENTER STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF OPEN LABEL SACUBITRIL/VALSARTAN IN PEDIATRIC PATIENTS WITH HEART FAILURE DUE TO SYSTEMIC LEFT VENTRICLE SYSTOLIC DYSFUNCTION WHO HAVE COMPLETED STUDY CLCZ696B2319. (P&S Industry Clinical Trial)

    Jan 1 2019 - Jan 1 2024

    DRUG REGISTRY TO PROSPECTIVELY DESCRIBE USE OF ROOM TEMPERATURE STABLE EPOPROSTENOL FOR INJECTION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (Private)

    Nov 10 2011 - Jun 30 2013

    ALLANTIBODIES IN CARDIAC TRANSPLANTATION - INTERVENTION, OUTCOMES AND MECHANISMS (Federal Gov)

    Mar 1 2012 - Aug 31 2012

    ALLANTIBODIES IN CARDIAC TRANSPLANTATION - INTERVENTION, OUT COMES AND MECHANISMS (Federal Gov)

    Mar 1 2009 - Feb 29 2012